

9 Literatur

1. Fialkow, P.J., R.J. Jacobson, and T. Papayannopoulou. (1977). Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. *Am J Med* **63**: 125-130.
2. Virchow, R. (1845). Weisses Blut. *Frorieps Notizen* **36**: 151-156.
3. Bennett, J.H. (1845). Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood. *Edinburgh Med. Surg. J.* 413-423.
4. Nowell, P.C. and D.A. Hungerford. (1960). Chromosome studies on normal and leukemic human leukocytes. *J Natl Cancer Inst* **25**: 85-109.
5. Nowell, P.C. and D.A. Hungerford. (1960). A minute chromosome in human chronic granulocytic leukemia. *Science* **132**: 1497-1501.
6. Faderl, S., M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, and H.M. Kantarjian. (1999). The biology of chronic myeloid leukemia. *N Engl J Med* **341**: 164-172.
7. Sillaber, C., M. Mayerhofer, H. Agis, V. Sagaster, C. Mannhalter, W.R. Sperr, K. Geissler, and P. Valent. (2003). Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. *Wien Klin Wochenschr* **115**: 485-504.
8. Gratwohl, A. (2003). Prognostic factors in chronic myeloid leukemia: allografting. *Semin Hematol* **40**: 13-21.
9. Rowley, J.D. (1973). Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* **243**: 290-293.
10. de Klein, A., A.G. van Kessel, G. Grosveld, C.R. Bartram, A. Hagemeijer, D. Bootsma, N.K. Spurr, N. Heisterkamp, J. Groffen, and J.R. Stephenson. (1982). A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. *Nature* **300**: 765-767.
11. Groffen, J., J.R. Stephenson, N. Heisterkamp, A. de Klein, C.R. Bartram, and G. Grosveld. (1984). Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. *Cell* **36**: 93-99.
12. Heisterkamp, N., K. Stam, J. Groffen, A. de Klein, and G. Grosveld. (1985). Structural organization of the bcr gene and its role in the Ph' translocation. *Nature* **315**: 758-761.
13. Ben-Neriah, Y., G.Q. Daley, A.M. Mes-Masson, O.N. Witte, and D. Baltimore. (1986). The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. *Science* **233**: 212-214.
14. Bernards, A., C.M. Rubin, C.A. Westbrook, M. Paskind, and D. Baltimore. (1987). The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. *Mol Cell Biol* **7**: 3231-3236.
15. Shtivelman, E., B. Lifshitz, R.P. Gale, and E. Canaani. (1985). Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. *Nature* **315**: 550-554.
16. Kurzrock, R., J.U. Gutterman, and M. Talpaz. (1988). The molecular genetics of Philadelphia chromosome-positive leukemias. *N Engl J Med* **319**: 990-998.
17. Fainstein, E., C. Marcelle, A. Rosner, E. Canaani, R.P. Gale, O. Dreazen, S.D. Smith, and C.M. Croce. (1987). A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. *Nature* **330**: 386-388.
18. Saglio, G., A. Guerrasio, C. Rosso, A. Zaccaria, A. Tassinari, A. Serra, G. Rege-Cambrin, U. Mazza, and F. Gavosto. (1990). New type of Bcr/Abl junction in

- Philadelphia chromosome-positive chronic myelogenous leukemia. *Blood* **76**: 1819-1824.
19. Wada, H., S. Mizutani, J. Nishimura, Y. Usuki, M. Kohsaki, M. Komai, H. Kaneko, S. Sakamoto, D. Delia, A. Kanamaru, and et al. (1995). Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. *Cancer Res* **55**: 3192-3196.
 20. Hariharan, I.K. and J.M. Adams. (1987). cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukaemia. *Embo J* **6**: 115-119.
 21. Shah, N.P., O.N. Witte, and C.T. Denny. (1991). Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines. *Mol Cell Biol* **11**: 1854-1860.
 22. Konopka, J.B., S.M. Watanabe, and O.N. Witte. (1984). An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. *Cell* **37**: 1035-1042.
 23. Muller, A.J., J.C. Young, A.M. Pendergast, M. Pondel, N.R. Landau, D.R. Littman, and O.N. Witte. (1991). BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. *Mol Cell Biol* **11**: 1785-1792.
 24. Grosveld, G., T. Verwoerd, T. van Agthoven, A. de Klein, K.L. Ramachandran, N. Heisterkamp, K. Stam, and J. Groffen. (1986). The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. *Mol Cell Biol* **6**: 607-616.
 25. Abelson, H.T. and L.S. Rabstein. (1970). Lymphosarcoma: virus-induced thymic-independent disease in mice. *Cancer Res* **30**: 2213-2222.
 26. Van Etten, R.A., P. Jackson, and D. Baltimore. (1989). The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. *Cell* **58**: 669-678.
 27. Van Etten, R.A., P.K. Jackson, D. Baltimore, M.C. Sanders, P.T. Matsudaira, and P.A. Janmey. (1994). The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. *J Cell Biol* **124**: 325-340.
 28. Mayer, B.J. and D. Baltimore. (1993). Signalling through SH2 and SH3 domains. *Trends Cell Biol* **3**: 8-13.
 29. Pawson, T. and G.D. Gish. (1992). SH2 and SH3 domains: from structure to function. *Cell* **71**: 359-362.
 30. Baskaran, R., L.D. Wood, L.L. Whitaker, C.E. Canman, S.E. Morgan, Y. Xu, C. Barlow, D. Baltimore, A. Wynshaw-Boris, M.B. Kastan, and J.Y. Wang. (1997). Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. *Nature* **387**: 516-519.
 31. Brown, L. and N. McCarthy. (1997). DNA repair. A sense-abl response? *Nature* **387**: 450-451.
 32. Kharbanda, S., R. Ren, P. Pandey, T.D. Shafman, S.M. Feller, R.R. Weichselbaum, and D.W. Kufe. (1995). Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. *Nature* **376**: 785-788.
 33. Lewis, J.M., R. Baskaran, S. Taagepera, M.A. Schwartz, and J.Y. Wang. (1996). Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. *Proc Natl Acad Sci USA* **93**: 15174-15179.

34. Sawyers, C.L., J. McLaughlin, A. Goga, M. Havlik, and O. Witte. (1994). The nuclear tyrosine kinase c-Abl negatively regulates cell growth. *Cell* **77**: 121-131.
35. Dai, Z. and A.M. Pendergast. (1995). Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. *Genes Dev* **9**: 2569-2582.
36. Jackson, P.K., M. Paskind, and D. Baltimore. (1993). Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. *Oncogene* **8**: 1943-1956.
37. Mayer, B.J. and D. Baltimore. (1994). Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. *Mol Cell Biol* **14**: 2883-2894.
38. Deininger, M.W., J.M. Goldman, and J.V. Melo. (2000). The molecular biology of chronic myeloid leukemia. *Blood* **96**: 3343-3356.
39. Hochhaus, A. und H. Rüdiger, *Chronische myeloische Leukämie*. 1 ed. 2001, Bremen: UNI-MED. 21-32.
40. Jonuleit, T., C. Peschel, R. Schwab, H. van der Kuip, E. Buchdunger, T. Fischer, C. Huber, and W.E. Aulitzky. (1998). Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. *Brit J Haematol* **100**: 295-303.
41. Pendergast, A.M., L.A. Quilliam, L.D. Cripe, C.H. Bassing, Z. Dai, N. Li, A. Batzer, K.M. Rabun, C.J. Der, J. Schlessinger, and et al. (1993). BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. *Cell* **75**: 175-185.
42. Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M.Z. Ratajczak, S.C. Wen, G. Zon, A.M. Gewirtz, B. Perussia, and B. Calabretta. (1995). Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. *Blood* **86**: 726-736.
43. Carlesso, N., D.A. Frank, and J.D. Griffin. (1996). Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. *J Exp Med* **183**: 811-820.
44. Cortez, D., G. Reuther, and A.M. Pendergast. (1997). The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. *Oncogene* **15**: 2333-2342.
45. Ilaria, R.L., Jr. and R.A. Van Etten. (1996). P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. *J Biol Chem* **271**: 31704-31710.
46. Puil, L., J. Liu, G. Gish, G. Mbamalu, D. Bowtell, P.G. Pelicci, R. Arlinghaus, and T. Pawson. (1994). Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. *Embo J* **13**: 764-773.
47. Feller, S.M., B. Knudsen, and H. Hanafusa. (1995). Cellular proteins binding to the first Src homology 3 (SH3) domain of the proto-oncogene product c-Crk indicate Crk-specific signaling pathways. *Oncogene* **10**: 1465-1473.
48. Neshat, M.S., A.B. Raitano, H.G. Wang, J.C. Reed, and C.L. Sawyers. (2000). The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. *Mol Cell Biol* **20**: 1179-1186.
49. Datta, S.R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M.E. Greenberg. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* **91**: 231-241.

50. del Peso, L., M. Gonzalez-Garcia, C. Page, R. Herrera, and G. Nunez. (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. *Science* **278**: 687-689.
51. Sattler, M. and R. Salgia. (1997). Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. *Cytokine Growth Factor Rev* **8**: 63-79.
52. Shuai, K., J. Halpern, J. ten Hoeve, X. Rao, and C.L. Sawyers. (1996). Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. *Oncogene* **13**: 247-254.
53. Sillaber, C., F. Gesbert, D.A. Frank, M. Sattler, and J.D. Griffin. (2000). STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. *Blood* **95**: 2118-2125.
54. Salgia, R., J.L. Li, D.S. Ewaniuk, W. Pear, E. Pisick, S.A. Burky, T. Ernst, M. Sattler, L.B. Chen, and J.D. Griffin. (1997). BCR/ABL induces multiple abnormalities of cytoskeletal function. *J Clin Invest* **100**: 46-57.
55. Verfaillie, C.M. (1999). Chronic myelogenous leukemia: from pathogenesis to therapy. *J Hematother* **8**: 3-13.
56. Mizejewski, G.J. (1999). Role of integrins in cancer: survey of expression patterns. *Proc Soc Exp Biol Med* **222**: 124-138.
57. Sawyers, C.L. (1999). Chronic myeloid leukemia. *N Engl J Med* **340**: 1330-1340.
58. Talpaz, M., H.M. Kantarjian, K. McCredie, J.M. Trujillo, M.J. Keating, and J.U. Gutterman. (1986). Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. *N Engl J Med* **314**: 1065-1069.
59. Kantarjian, H., J.V. Melo, S. Tura, S. Giralt, and M. Talpaz. (2000). Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. *Hematology (Am Soc Hematol Educ Program)* 90-109.
60. Stark, G.R., I.M. Kerr, B.R. Williams, R.H. Silverman, and R.D. Schreiber. (1998). How cells respond to interferons. *Annu Rev Biochem* **67**: 227-264.
61. Druker, B.J., C.L. Sawyers, R. Capdeville, J.M. Ford, M. Baccarani, and J.M. Goldman. (2001). Chronic myelogenous leukemia. *Hematology (Am Soc Hematol Educ Program)* 87-112.
62. Capdeville, R., E. Buchdunger, J. Zimmermann, and A. Matter. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. *Nat Rev Drug Discov* **1**: 493-502.
63. Schindler, T., W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. *Science* **289**: 1938-1942.
64. Goldman, J.M. (2000). Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. *Lancet* **355**: 1031-1032.
65. Melo, J.V., T.P. Hughes, and J.F. Apperley. (2003). Chronic myeloid leukemia. *Hematology (Am Soc Hematol Educ Program)* 132-152.
66. von Bubnoff, N., C. Peschel, and J. Duyster. (2003). Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. *Leukemia* **17**: 829-838.
67. Weisberg, E. and J.D. Griffin. (2003). Resistance to imatinib (Glivec): update on clinical mechanisms. *Drug Resist Updat* **6**: 231-238.

68. Gratwohl, A., J. Hermans, J. Apperley, W. Arcese, A. Bacigalupo, G. Bandini, P. di Bartolomeo, M. Boogaerts, A. Bosi, E. Carreras, and et al. (1995). Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working party chronic leukemia of the european group for blood and marrow transplantation. *Blood* **86**: 813-818.
69. Storek, J., T. Gooley, M. Siadak, W.I. Bensinger, D.G. Maloney, T.R. Chauncey, M. Flowers, K.M. Sullivan, R.P. Witherspoon, S.D. Rowley, J.A. Hansen, R. Storb, and F.R. Appelbaum. (1997). Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. *Blood* **90**: 4705-4709.
70. Antin, J.H. (1993). Graft-versus-leukemia: no longer an epiphenomenon. *Blood* **82**: 2273-2277.
71. Horowitz, M.M., R.P. Gale, P.M. Sondel, J.M. Goldman, J. Kersey, H.J. Kolb, A.A. Rimm, O. Ringden, C. Rozman, B. Speck, and et al. (1990). Graft-versus-leukemia reactions after bone marrow transplantation. *Blood* **75**: 555-562.
72. Jones, R.J. and A. Bedi. (1994). Biology of chronic myeloid leukemia and its relevance to autologous bone marrow transplantation. *Curr Opin Oncol* **6**: 122-126.
73. Zinkernagel, R.M. and P.C. Doherty. (1974). Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. *Nature* **251**: 547-548.
74. Bjorkman, P.J. and P. Parham. (1990). Structure, function, and diversity of class I major histocompatibility complex molecules. *Annu Rev Biochem* **59**: 253-288.
75. Townsend, A. and H. Bodmer. (1989). Antigen recognition by class I-restricted T lymphocytes. *Annu Rev Immunol* **7**: 601-624.
76. Cunliffe, V. and J. Trowsdale. (1987). The molecular genetics of human chromosome 6. *J Med Genet* **24**: 649-658.
77. Faber, H.E., R.S. Kucherlapati, M.D. Poulík, F.H. Ruddle, and O. Smithies. (1976). beta2-Microglobulin locus on human chromosome 15. *Somatic Cell Genet* **2**: 141-153.
78. Mehra, N.K. and G. Kaur. (2003). MHC-based vaccination approaches: progress and perspectives. *Expert Rev Mol Med* **2003**: 1-17.
79. Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. Strominger, and D.C. Wiley. (1987). Structure of the human class I histocompatibility antigen, HLA-A2. *Nature* **329**: 506-512.
80. Hughes, A.L. and M. Nei. (1988). Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. *Nature* **335**: 167-170.
81. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H.G. Rammensee. (1991). Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature* **351**: 290-296.
82. Rammensee, H.G., K. Falk, and O. Rotzschke. (1993). MHC molecules as peptide receptors. *Curr Opin Immunol* **5**: 35-44.
83. Goldberg, A.L. and K.L. Rock. (1992). Proteolysis, proteasomes and antigen presentation. *Nature* **357**: 375-379.
84. Coux, O., K. Tanaka, and A.L. Goldberg. (1996). Structure and functions of the 20S and 26S proteasomes. *Annu Rev Biochem* **65**: 801-847.
85. Uebel, S. and R. Tampe. (1999). Specificity of the proteasome and the TAP transporter. *Curr Opin Immunol* **11**: 203-208.

86. Groettrup, M., R. Kraft, S. Kostka, S. Standera, R. Stohwasser, and P.M. Kloetzel. (1996). A third interferon-gamma-induced subunit exchange in the 20S proteasome. *Eur J Immunol* **26**: 863-869.
87. Groettrup, M., T. Ruppert, L. Kuehn, M. Seeger, S. Standera, U. Koszinowski, and P.M. Kloetzel. (1995). The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. *J Biol Chem* **270**: 23808-23815.
88. Akiyama, K., K. Yokota, S. Kagawa, N. Shimbara, T. Tamura, H. Akioka, H.G. Nothwang, C. Noda, K. Tanaka, and A. Ichihara. (1994). cDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y. *Science* **265**: 1231-1234.
89. Belich, M.P., R.J. Glynn, G. Senger, D. Sheer, and J. Trowsdale. (1994). Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. *Curr Biol* **4**: 769-776.
90. Gaczynska, M., K.L. Rock, T. Spies, and A.L. Goldberg. (1994). Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. *Proc Natl Acad Sci USA* **91**: 9213-9217.
91. Hershko, A. and A. Ciechanover. (1998). The ubiquitin system. *Annu Rev Biochem* **67**: 425-479.
92. Galvin, K., S. Krishna, F. Ponchel, M. Frohlich, D.E. Cummings, R. Carlson, J.R. Wands, K.J. Isselbacher, S. Pillai, and M. Ozturk. (1992). The major histocompatibility complex class I antigen-binding protein p88 is the product of the calnexin gene. *Proc Natl Acad Sci U S A* **89**: 8452-8456.
93. Vassilakos, A., M.F. Cohen-Doyle, P.A. Peterson, M.R. Jackson, and D.B. Williams. (1996). The molecular chaperone calnexin facilitates folding and assembly of class I histocompatibility molecules. *Embo J* **15**: 1495-1506.
94. Grandea, A.G., 3rd, P.J. Lehner, P. Cresswell, and T. Spies. (1997). Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin. *Immunogenetics* **46**: 477-483.
95. Sadasivan, B., P.J. Lehner, B. Ortmann, T. Spies, and P. Cresswell. (1996). Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. *Immunity* **5**: 103-114.
96. Starr, T.K., S.C. Jameson, and K.A. Hogquist. (2003). Positive and negative selection of T cells. *Annu Rev Immunol* **21**: 139-176.
97. Tseng, S.Y. and M.L. Dustin. (2002). T-cell activation: a multidimensional signaling network. *Curr Opin Cell Biol* **14**: 575-580.
98. Schwartz, R.H. (2003). T cell anergy. *Annu Rev Immunol* **21**: 305-334.
99. Klein, G., H.O. Sjogren, E. Klein, and K.E. Hellstrom. (1960). Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. *Cancer Res* **20**: 1561-1572.
100. Prehn, R.T. and J.M. Main. (1957). Immunity to methylcholanthrene-induced sarcomas. *J Natl Cancer Inst* **18**: 769-778.
101. Burnet, F.M. (1970). The concept of immunological surveillance. *Prog Exp Tumor Res* **13**: 1-27.
102. Nagorsen, D., C. Scheibenbogen, F.M. Marincola, A. Letsch, and U. Keilholz. (2003). Natural T cell immunity against cancer. *Clin Cancer Res* **9**: 4296-4303.
103. Gabrilovich, D. and V. Pisarev. (2003). Tumor escape from immune response: mechanisms and targets of activity. *Curr Drug Targets* **4**: 525-536.

104. Rammensee, H.G., T. Weinschenk, C. Gouttefangeas, and S. Stevanovic. (2002). Towards patient-specific tumor antigen selection for vaccination. *Immunol Rev* **188**: 164-176.
105. Van den Eynde, B.J. and P. van der Bruggen. (1997). T cell defined tumor antigens. *Curr Opin Immunol* **9**: 684-693.
106. Weber, J. (2002). Peptide vaccines for cancer. *Cancer Invest* **20**: 208-221.
107. Schultze, J.L. and R.H. Vonderheide. (2001). From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. *Trends Immunol* **22**: 516-523.
108. Schirle, M., W. Keilholz, B. Weber, C. Gouttefangeas, T. Dumrese, H.D. Becker, S. Stevanovic, and H.G. Rammensee. (2000). Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. *Eur J Immunol* **30**: 2216-2225.
109. Schirle, M., T. Weinschenk, and S. Stevanovic. (2001). Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. *J Immunol Methods* **257**: 1-16.
110. Weinschenk, T., C. Gouttefangeas, M. Schirle, F. Obermayr, S. Walter, O. Schoor, R. Kurek, W. Loeser, K.H. Bichler, D. Wernet, S. Stevanovic, and H.G. Rammensee. (2002). Integrated functional genomics approach for the design of patient-individual antitumor vaccines. *Cancer Res* **62**: 5818-5827.
111. Grosveld, G., A. Hermans, A. De Klein, D. Bootsma, N. Heisterkamp, and J. Groffen. (1987). The role of the Philadelphia translocation in chronic myelocytic leukemia. *Ann N Y Acad Sci* **511**: 262-269.
112. Bocchia, M., P.A. Wentworth, S. Southwood, J. Sidney, K. McGraw, D.A. Scheinberg, and A. Sette. (1995). Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. *Blood* **85**: 2680-2684.
113. Bocchia, M., T. Korontsvit, Q. Xu, S. Mackinnon, S.Y. Yang, A. Sette, and D.A. Scheinberg. (1996). Specific human cellular immunity to bcr-abl oncogene-derived peptides. *Blood* **87**: 3587-3592.
114. Greco, G., D. Fruci, D. Accapezzato, V. Barnaba, R. Nisini, G. Alimena, E. Montefusco, E. Vigneti, R. Butler, N. Tanigaki, and R. Tosi. (1996). Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. *Leukemia* **10**: 693-699.
115. Norbury, L.C., R.E. Clark, and S.E. Christmas. (2000). b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. *Brit J Haematol* **109**: 616-621.
116. Yotnda, P., H. Firat, F. Garcia-Pons, Z. Garcia, G. Gourru, J.P. Vernant, F.A. Lemonnier, V. Leblond, and P. Langlade-Demoyen. (1998). Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. *J Clin Invest* **101**: 2290-2296.
117. Posthuma, E.F., J.H. Falkenburg, J.F. Apperley, A. Gratwohl, E. Roosnek, B. Hertenstein, R.F. Schipper, G.M. Schreuder, J. D'Amaro, M. Oudshoorn, J.H. van Biezen, J. Hermans, R. Willemze, and D. Niederwieser. (1999). HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. *Blood* **93**: 3863-3865.
118. Eibl, B., S. Ebner, C. Duba, G. Bock, N. Romani, M. Erdel, A. Gachter, D. Niederwieser, and G. Schuler. (1997). Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia

- translocation and can induce a CML-specific primary cytotoxic T-cell response. *Genes Chromosomes Cancer* **20**: 215-223.
119. Nieda, M., A. Nicol, A. Kikuchi, K. Kashiwase, K. Taylor, K. Suzuki, K. Tadokoro, and T. Juji. (1998). Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. *Blood* **91**: 977-983.
 120. Westermann, J., J. Kopp, I. Körner, G. Richter, Z. Qin, T. Blankenstein, B. Dörken, and A. Pezzutto. (2000). Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia. *Bone Marrow Transplant* **25 Suppl 2**: 46-49.
 121. Stam, N.J., H. Spits, and H.L. Ploegh. (1986). Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. *J Immunol* **137**: 2299-2306.
 122. Stam, N.J., T.M. Vroom, P.J. Peters, E.B. Pastoors, and H.L. Ploegh. (1990). HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. *Int Immunol* **2**: 113-125.
 123. Parham, P. and F.M. Brodsky. (1981). Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. *Hum Immunol* **3**: 277-299.
 124. Berger, A.E., J.E. Davis, and P. Cresswell. (1982). Monoclonal antibody to HLA-A3. *Hybridoma* **1**: 87-90.
 125. Barnstable, C.J., W.F. Bodmer, G. Brown, G. Galfre, C. Milstein, A.F. Williams, and A. Ziegler. (1978). Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. *Cell* **14**: 9-20.
 126. Kavathas, P., F.H. Bach, and R. DeMars. (1980). Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. *Proc Natl Acad Sci USA* **77**: 4251-4255.
 127. DeMars, R., C.C. Chang, S. Shaw, P.J. Reitnauer, and P.M. Sondel. (1984). Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. *Hum Immunol* **11**: 77-97.
 128. DeMars, R., R. Rudersdorf, C. Chang, J. Petersen, J. Strandtmann, N. Korn, B. Sidwell, and H.T. Orr. (1985). Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. *Proc Natl Acad Sci USA* **82**: 8183-8187.
 129. Vitiello, A., D. Marchesini, J. Furze, L.A. Sherman, and R.W. Chesnut. (1991). Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. *J Exp Med* **173**: 1007-1015.
 130. Sambrook, J., E.F. Fritsch, and T. Maniatis, *Molecular cloning: A Laboratory Course Manual*. 1989, New York: Cold Spring Harbor Laboratory Press.
 131. Brown, T.A., *Manipulation of purified DNA*, in *Gene Cloning*, C. Hall, Editor. 1995: Manchester. 52-86.
 132. Feinberg, A.P. and B. Vogelstein. (1984). A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Addendum. *Anal Biochem* **137**: 266-267.
 133. Blum, H., Beier, H. und Gross, H.J. (1987). Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. *Electrophoresis* **8**: 93-99.

-
134. Spies, T., M. Bresnahan, S. Bahram, D. Arnold, G. Blanck, E. Mellins, D. Pious, and R. DeMars. (1990). A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. *Nature* **348**: 744-747.
135. Griffin, T.A., D. Nandi, M. Cruz, H.J. Fehling, L.V. Kaer, J.J. Monaco, and R.A. Colbert. (1998). Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. *J Exp Med* **187**: 97-104.
136. Seeger, F.H., M. Schirle, J. Gatfield, D. Arnold, W. Keilholz, P. Nickolaus, H.G. Rammensee, and S. Stevanovic. (1999). The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis. *Immunogenetics* **49**: 571-576.
137. Kellner, R., F. Lottspeich, and H.E. Meyer, *Microcharacterization of Proteins*. 2 ed. *Sequence Analysis of Proteins and Peptides by Mass Spectrometry*, ed. C. Siethoff, C. Lohaus, and H.E. Meyer. 1999, Weinheim: Wiley-VCH. 245-273.
138. Benz, E.J., Jr., M.J. Murnane, B.L. Tonkonow, B.W. Berman, E.M. Mazur, C. Cavallese, T. Jenko, E.L. Snyder, B.G. Forget, and R. Hoffman. (1980). Embryonic-fetal erythroid characteristics of a human leukemic cell line. *Proc Natl Acad Sci U S A* **77**: 3509-3513.
139. Drew, S.I., P.I. Terasaki, R.J. Billing, O.J. Bergh, J. Minowada, and E. Klein. (1977). Group-specific human granulocyte antigens on a chronic myelogenous leukemia cell line with a Philadelphia chromosome marker. *Blood* **49**: 715-718.
140. Garson, D., M.C. Dokhelar, H. Wakasugi, Z. Mishal, and T. Tursz. (1985). HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon. *Exp Hematol* **13**: 885-890.
141. Klein, G., J. Zeuthen, I. Eriksson, P. Terasaki, M. Bernoco, A. Rosen, G. Masucci, S. Povey, and R. Ber. (1980). Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). *J Natl Cancer Inst* **64**: 725-738.
142. Maziarz, R.T., S.J. Burakoff, and D.V. Faller. (1990). The regulation of exogenous and endogenous class I MHC genes in a human tumor cell line, K562. *Mol Immunol* **27**: 135-142.
143. Oh, H.S., H. Kwon, S.K. Sun, and C.H. Yang. (2002). QM, a putative tumor suppressor, regulates proto-oncogene c-yes. *J Biol Chem* **277**: 36489-36498.
144. Mousses, S., L. Bubendorf, U. Wagner, G. Hostetter, J. Kononen, R. Cornelison, N. Goldberger, A.G. Elkahloun, N. Willi, P. Koivisto, W. Ferhle, M. Raffeld, G. Sauter, and O.P. Kallioniemi. (2002). Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. *Cancer Res* **62**: 1256-1260.
145. Visvader, J.E., D. Venter, K. Hahm, M. Santamaria, E.Y. Sum, L. O'Reilly, D. White, R. Williams, J. Armes, and G.J. Lindeman. (2001). The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. *Proc Natl Acad Sci USA* **98**: 14452-14457.
146. Grutz, G., A. Forster, and T.H. Rabbitts. (1998). Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia. *Oncogene* **17**: 2799-2803.
147. Hacein-Bey-Abina, S., C. Von Kalle, M. Schmidt, M.P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C.S. Osborne, R. Pawliuk, E. Morillon, R. Sorensen, A. Forster, P. Fraser, J.I. Cohen, G. de Saint Basile, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L.E. Leiva, M. Wissler, C. Prinz, T.H.
-

- Rabbitts, F. Le Deist, A. Fischer, and M. Cavazzana-Calvo. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* **302**: 415-419.
148. McCormack, M.P. and T.H. Rabbitts. (2004). Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. *N Engl J Med* **350**: 913-922.
149. Asch, H.L., K. Head, Y. Dong, F. Natoli, J.S. Winston, J.L. Connolly, and B.B. Asch. (1996). Widespread loss of gelsolin in breast cancers of humans, mice, and rats. *Cancer Res* **56**: 4841-4845.
150. Dong, Y., H.L. Asch, D. Medina, C. Ip, M. Ip, R. Guzman, and B.B. Asch. (1999). Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers. *Int J Cancer* **81**: 930-938.
151. Habeck, M. (1999). Gelsolin: a new marker for breast cancer? *Mol Med Today* **5**: 503.
152. Shields, J.M., K. Rogers-Graham, and C.J. Der. (2002). Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. *J Biol Chem* **277**: 9790-9799.
153. Janke, J., K. Schluter, B. Jandrig, M. Theile, K. Kolble, W. Arnold, E. Grinstein, A. Schwartz, L. Estevez-Schwarz, P.M. Schlag, B.M. Jockusch, and S. Scherneck. (2000). Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. *J Exp Med* **191**: 1675-1686.
154. Wittenmayer, N., B. Jandrig, M. Rothkegel, K. Schluter, W. Arnold, W. Haensch, S. Scherneck, and B.M. Jockusch. (2004). Tumor suppressor activity of profilin requires a functional actin binding site. *Mol Biol Cell* **15**: 1600-1608.
155. Iervolino, A., G. Santilli, R. Trotta, C. Guerzoni, V. Cesi, A. Bergamaschi, C. Gambacorti-Passerini, B. Calabretta, and D. Perrotti. (2002). hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. *Mol Cell Biol* **22**: 2255-2266.
156. Galande, S. (2002). Chromatin (dis)organization and cancer: BUR-binding proteins as biomarkers for cancer. *Curr Cancer Drug Targets* **2**: 157-190.
157. Yow, H.K., J.M. Wong, H.S. Chen, C.G. Lee, S. Davis, G.D. Steele, Jr., and L.B. Chen. (1988). Increased mRNA expression of a laminin-binding protein in human colon carcinoma: complete sequence of a full-length cDNA encoding the protein. *Proc Natl Acad Sci USA* **85**: 6394-6398.
158. Rabbitts, T.H. (1998). LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. *Genes Dev* **12**: 2651-2657.
159. Rabbitts, T.H., K. Bucher, G. Chung, G. Grutz, A. Warren, and Y. Yamada. (1999). The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development. *Cancer Res* **59**: 1794-1798.
160. Wittlin, S., E.Y. Sum, N.K. Jonas, G.J. Lindeman, and J.E. Visvader. (2003). Two promoters within the human LMO4 gene contribute to its overexpression in breast cancer cells. *Genomics* **82**: 280-287.
161. Cleary, M.L., J.D. Mellentin, J. Spies, and S.D. Smith. (1988). Chromosomal translocation involving the beta T cell receptor gene in acute leukemia. *J Exp Med* **167**: 682-687.
162. Mellentin, J.D., S.D. Smith, and M.L. Cleary. (1989). Iyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. *Cell* **58**: 77-83.

-
163. So, C.W., M. Lin, P.M. Ayton, E.H. Chen, and M.L. Cleary. (2003). Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. *Cancer Cell* **4**: 99-110.
 164. Ayton, P.M. and M.L. Cleary. (2001). Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. *Oncogene* **20**: 5695-5707.
 165. Racevskis, J., A. Dill, J.A. Sparano, and H. Ruan. (1999). Molecular cloning of LMO41, a new human LIM domain gene. *Biochim Biophys Acta* **1445**: 148-153.
 166. Gambacorti-Passerini, C., P. le Coutre, L. Mologni, M. Fanelli, C. Bertazzoli, E. Marchesi, M. Di Nicola, A. Biondi, G.M. Corneo, D. Belotti, E. Pogliani, and N.B. Lydon. (1997). Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. *Blood Cells Mol Dis* **23**: 380-394.
 167. Rock, K.L. and A.L. Goldberg. (1999). Degradation of cell proteins and the generation of MHC class I-presented peptides. *Annu Rev Immunol* **17**: 739-779.
 168. Saveanu, L., D. Fruci, and P. van Endert. (2002). Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. *Mol Immunol* **39**: 203-215.
 169. Gromme, M. and J. Neefjes. (2002). Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. *Mol Immunol* **39**: 181-202.
 170. Morel, S., F. Levy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A.L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.C. Cerottini, T. Boon, J.E. Gairin, and B.J. Van den Eynde. (2000). Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. *Immunity* **12**: 107-117.
 171. Van den Eynde, B.J. and S. Morel. (2001). Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. *Curr Opin Immunol* **13**: 147-153.
 172. Brockman, A.H., R. Orlando, and R.L. Tarleton. (1999). A new liquid chromatography/tandem mass spectrometric approach for the identification of class I major histocompatibility complex associated peptides that eliminates the need for bioassays. *Rapid Commun Mass Spectrom* **13**: 1024-1030.
 173. Lemmel, C. and S. Stevanovic. (2003). The use of HPLC-MS in T-cell epitope identification. *Methods* **29**: 248-259.
 174. Rammensee, H.G. (1997). Informationstransfer durch MHC-Moleküle. *Biospektrum* **1**: 35-40.
 175. Yoon, S.J., J.O. Kang, J.S. Park, N.K. Kim, and D.S. Heo. (2000). Reduced expression of MHC class I antigen in human cancer cell lines with defective LMP-7. *Anticancer Res* **20**: 949-953.
 176. Van Kaer, L., P.G. Ashton-Rickardt, H.L. Ploegh, and S. Tonegawa. (1992). TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. *Cell* **71**: 1205-1214.
 177. Yewdell, J.W. (2001). Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. *Trends Cell Biol* **11**: 294-297.
 178. Koopmann, J.O., J. Albring, E. Huter, N. Bulbuc, P. Spee, J. Neefjes, G.J. Hammerling, and F. Momburg. (2000). Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. *Immunity* **13**: 117-127.

-
179. Storkus, W.J., H.J. Zeh, 3rd, R.D. Salter, and M.T. Lotze. (1993). Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. *J Immunother* **14**: 94-103.
180. Clark, R.E., I.A. Dodi, S.C. Hill, J.R. Lill, G. Aubert, A.R. Macintyre, J. Rojas, A. Bourdon, P.L. Bonner, L. Wang, S.E. Christmas, P.J. Travers, C.S. Creaser, R.C. Rees, and J.A. Madrigal. (2001). Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. *Blood* **98**: 2887-2893.
181. Chung, E.J., S.G. Hwang, P. Nguyen, S. Lee, J.S. Kim, J.W. Kim, P.A. Henkart, D.P. Bottaro, L. Soon, P. Bonvini, S.J. Lee, J.E. Karp, H.J. Oh, J.S. Rubin, and J.B. Trepel. (2002). Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. *Blood* **100**: 982-990.
182. Grisolano, J.L., G.M. Sclar, and T.J. Ley. (1994). Early myeloid cell-specific expression of the human cathepsin G gene in transgenic mice. *Proc Natl Acad Sci USA* **91**: 8989-8993.
183. Papadopoulos, K.P., N. Suci-Foca, C.S. Hesdorffer, S. Tugulea, A. Maffei, and P.E. Harris. (1997). Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. *Blood* **90**: 4938-4946.
184. Ferrando, A.A., S. Herblot, T. Palomero, M. Hansen, T. Hoang, E.A. Fox, and A.T. Look. (2004). Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. *Blood* **103**: 1909-1911.
185. Erfurth, F., C.S. Hemenway, A.C. de Erkenez, and P.H. Domer. (2004). MLL fusion partners AF4 and AF9 interact at subnuclear foci. *Leukemia* **18**: 92-102.
186. Tse, E., G. Grutz, A.A. Garner, Y. Ramsey, N.P. Carter, N. Copeland, D.J. Gilbert, N.A. Jenkins, A. Agulnick, A. Forster, and T.H. Rabbitts. (1999). Characterization of the Lmo4 gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping. *Mamm Genome* **10**: 1089-1094.
187. Yamada, Y., R. Pannell, A. Forster, and T.H. Rabbitts. (2002). The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. *Oncogene* **21**: 1309-1315.
188. Yamada, Y., A.J. Warren, C. Dobson, A. Forster, R. Pannell, and T.H. Rabbitts. (1998). The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. *Proc Natl Acad Sci USA* **95**: 3890-3895.
189. Nguyen, T., *Charakterisierung eines durch Peptidelution identifizierten Tumorantigens*. 2003, Technische Fachhochschule Berlin: Berlin.
190. Sum, E.Y., B. Peng, X. Yu, J. Chen, J. Byrne, G.J. Lindeman, and J.E. Visvader. (2002). The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. *J Biol Chem* **277**: 7849-7856.
191. Deutsch, E., S. Jarrousse, D. Buet, A. Dugray, M.L. Bonnet, M.C. Vozenin-Brotans, F. Guilhot, A.G. Turhan, J. Feunteun, and J. Bourhis. (2003). Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. *Blood* **101**: 4583-4588.
192. Ostendorff, H.P., R.I. Peirano, M.A. Peters, A. Schluter, M. Bossenz, M. Scheffner, and I. Bach. (2002). Ubiquitination-dependent cofactor exchange on LIM homeodomain transcription factors. *Nature* **416**: 99-103.
193. Nagaraju, K. (2001). Immunological capabilities of skeletal muscle cells. *Acta Physiol Scand* **171**: 215-223.
-

194. Williams, K.A., D.N. Hart, J.W. Fabre, and P.J. Morris. (1980). Distribution and quantitation of HLA-ABC and DR (Ia) antigens on human kidney and other tissues. *Transplantation* **29**: 274-279.
195. Fuchs, U., G. Rehkamp, O.A. Haas, R. Slany, M. König, S. Bojesen, R.M. Bohle, C. Damm-Welk, W.D. Ludwig, J. Harbott, and A. Borkhardt. (2001). The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia. *Proc Natl Acad Sci USA* **98**: 8756-8761.